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Infection with Helicobacter pylori is strongly associated with gastric cancer and gastric adenocarcinoma. WHO classiﬁed H. pylori
as a group 1 carcinogen in 1994. Impatiens balsamina L. has been used as indigenous medicine in Asia for the treatment of
rheumatism, fractures and ﬁngernail inﬂammation. In this study, we isolated anti-H. pylori compounds from this plant and
investigated their anti- and bactericidal activity. Compounds of 2-methoxy-1,4-naphthoquinone (MeONQ) and stigmasta-7,22-
diene-3β-ol (spinasterol) were isolated from the pods and roots/stems/leaves of I. balsamina L., respectively. The minimum
inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) for MeONQ were in the ranges of 0.156–
0.625 and 0.313–0.625 μgm L −1, respectively, and in the ranges of 20–80μgm L −1 both of MICs and MBCs for spinasterol against
antibiotic (clarithromycin, metronidazole and levoﬂoxacin) resistant H. pylori.N o t a b l y ,t h ea c t i v i t yo fM e O N Qw a se q u i v a l e n tt o
thatofamoxicillin(AMX).ThebactericidalH.pyloriactionofMeONQwasdose-dependent.Furthermore,theactivityofMeONQ
was not inﬂuenced by the environmental pH values (4–8) and demonstrated good thermal (121◦C for 15 min) stability. MeONQ
aboundsintheI.balsaminaL.podatthelevelof4.39%(w/wdb).Inconclusion,MeONQexhibitsstrongpotentialtobedeveloped
as a candidate agent for the eradication of H. pylori infection.
1.Introduction
Infection with Helicobacter pylori is strongly associated
with gastric cancer and gastric adenocarcinoma [1]. WHO
classiﬁed H. pylori as a group 1 carcinogen in 1994. Antibi-
otics combined with proton-pump inhibitors, H2-blockers
and bismuth salts are the suggested standard treatment
modalities to eradicate H. pylori [2]. However, H. pylori
resistance to antibiotics is thought to be the most impor-
tant factor in eradication failure. Resistance rates are the
highest for metronidazole (MTZ) (19.9–39.2%), followed
by clarithromycin (CLR) (1.7–27.7%), and the lowest for
amoxicillin (AMX), tetracycline and trovaﬂoxacin (0–4.7%)
[3, 4].
Impatiens balsamina L. (Balsaminaceae) is an annual
herb which originated in Asia. The whole plant has been
used as indigenous medicine in Taiwan for the treatment of
rheumatism, swelling and ﬁngernail inﬂammation. Modern
pharmacological studies have reported this plant demon-
strating antifungal, antibacterial, antitumor, antipruritic and
antianaphylactic activities [5, 6] .T h ea c t i v ec o m p o u n d s
isolated from this plant include peptides (Ib-AMP1-4) from
seeds, quinones[1, 4-naphthoquinone, lawsone, 2-methoxy-
1,4-naphthoquinone (MeONQ), balsaquinone, impatienol,
naphthalene-1,4-dione] from petals, pericarp and aerial
parts, and ﬂavonoids (kaempferol, quercetin, rutin, astra-
galin, nicotiﬂorin, naringenin and their derivatives) from
petals and leaves [5–8].2 Evidence-Based Complementary and Alternative Medicine
MeONQ (Figure 1) was isolated from the genus of Impa-
tiens including I. balsamina L., I. bicolor and I. glandulifera
Royl [7–10]. The plant Swertia calycina (Gentianaceae) was
alsofoundtocontainthiscompound[11].Somebioactivities
were demonstrated in MeONQ including antipruritic [12],
antiinﬂammatory,antiallergic[13]andanticancer[14]activ-
ities. Furthermore, reducing oral lesion recurrence in human
immunodeﬁciency virus patients was also reported for this
compound [15]. Antimicrobial activity against fungal and
bacterial pathogens were also published [7, 16].
Spinasterol (Figure 1) was isolated from the plants of I.
balsamina, Adenophora tetraphylla, Medicago sativa, Poly-
althia cerasoides Bedd and Pueraria miriﬁca [8, 17–20]. The
bioactivity reported in spinasterol includes antibacterial
action against Streptococcus mutans and S. sorbrinus [19]a n d
antitumor eﬀect against breast, ovarian and skin cancer cells
[20].
In our previous study, we revealed the whole plant of I.
balsamina L. exhibiting strong bactericidal H. pylori activity,
especially, the acetone and ethyl acetate pod extracts. This
activity was higher than any previously reported natural
products [21].
Therefore, in the current study, we isolated anti-H. pylori
compounds from I. balsamina L., in which a silica gel chro-
matography was used. Minimum inhibiory concentrations
(MICs), minimum bactericidal concentrations (MBCs),
time-kill assay, eﬀect of environmental pH, and thermal
stability of the isolated compounds were examined. Multiple
antibiotic-resistant H. pylori strains were used in the tests.
2. Methods
2.1. Plant Materials. Impatiens balsamina L. (white ﬂower)
were collected from a local farm in Erhshuei township
between May 2007 and August 2007, which were identiﬁed
by Professor Yang-Shiun Chang from the Institute of the
Chinese Pharmaceutical Science China Medical University.
Voucher specimens (No. 258526) were deposited at the
InstituteofEcologyandEvolutionaryBiology,CollegeofLife
Science, National Taiwan University. The parts of pods and
mixed roots/stems/leaves were dried by a warm stream of
air (below 60◦C) and ground (0.25mm particle size) for the
anti-H. pylori compounds isolation.
2.2. Extraction and Isolation. The I. balsamina L. pod extract
was prepared according to Wang and Huang [22]. In brief,
a mixture of 100g of pod sample and 700mL of acetone
was stirred at room temperature for 1h, and then was
centrifuged at 13,666g for 15min at 4◦C. The residue was
extracted twice more with 700mL of acetone of each time.
All the supernatants were collected and concentrated in a
rotary vacuum evaporator at less than 40◦C, and thus the
pod extract (7.28g) was obtained. This extract was subjected
to a silica gel column [Kiesel gel 60 (40–63μm), Merck,
Germany; 2.5cm i.d. × 33cm] chromatography eluted with
dichloromethane-methanol (150:1, v/v) to develop two
bands in the column. The upper band was collected and
subjected to the second silica gel column chromatography
eluted with ethyl acetate-dichloromethane (1:1); one
band was developed in the column and was collected.
The collected fraction was subjected to the third silica gel
column chromatography orderly eluted with n-hexane-ethyl
acetate(10:0,9:1,8:2).Fromthe8:2elution,oneband
was developed in the column and was collected to yield
compound (1) (2.61g).
Samples (100g) of roots/stems/leaves were extracted
with 95% ethanol according to the aforementioned method
and 13.11g of extract were obtained. This extract was
fractionatedwithwaterandn-hexane.Then-hexanefraction
was collected (1.88g) and subjected to a silica gel column
chromatography orderly eluted with n-hexane-ethyl acetate
(10:0, 9:1 and 8:2) to yield two bands in the column from
the 8:2 elution. The lower band was collected (0.638g) and
then subjected to the second silica gel column chromatog-
raphy orderly eluted with n-hexane–ethyl acetate (100:0,
95:5, 90:10, 85:15). From the 85:15 elution, two bands
were developed in the column. The upper band was collected
and subjected to the third silica gel column chromatography
eluted with n-hexane–ethyl acetate (75:25) to give three
bands in the column. The middle band was collected to yield
compound (2) (0.089g).
2.3. Instrumentations. UV and IR spectra were recorded on
a UV/Visible Hitachi U-2800 (Japan) spectrophotometer
and a Bruker Equinox 55 (USA) FTIR, respectively. 1H
and 13C NMR spectra were recorded at 600 and 150MHz,
respectively, on a Varian Inova 600 (USA) spectrometer.
Chemical shifts are reported in δ units (ppm) and coupling
constants (J)i nH Z.C D C l 3 (Sigma-Aldrich, St. Louis, MO,
USA) was used as the solvent and TMS (Sigma-Aldrich, St.
Louis, MO, USA) as the internal standard, in which chemical
shifts for CDCl3 were δH 7.266 and δC 77.335. MS spectra
were measured on a EI-Finnigan/Thermo Quest MAT 95 XL
(Germany) mass spectrometer. Melting point was performed
on the Mel-Temp (USA).
2.4. Bacterial Strains and Cultivation. Helicobacter pylori
strains of ATCC 700824, 43504, and 43526 were obtained
from American Type Culture Collection (ATCC). Helicobac-
ter pylori strains of KMUH 4917, 4952, and 4967 were
isolated from the stomach of patients from Chung-Ho
Memorial Hospital, Kaohsiung Medical University. Of these
H. pylori strains, the three ATCC strains have resistance to
MTZ, the three clinical strains are cross-resistance to CLR,
MTZ and levoﬂoxacin (LVX); and all the test strains are
sensitive to AMX.
Av o l u m eo f0 . 1m Lo fH. pylori suspension was added
in 5mL tryptic soy broth (TSB, Difco, USA, pH 7.3), with
Columbia agar (bioM´ erieux, France, pH 7.3) slant contain-
ing 5% (v/v) deﬁbrinated sheep blood formed at the bottom
ofthetesttube.Thebrothwasincubatedinamicroaerophilic
jarsystem(BBL,USA;5%O 2 and10%CO2 inair,anOXOID
BR 056A gas-generating kit was used) at 37◦Cf o r7 2 ht o
produce 0.5–2.0 × 107 cfumL−1 of the bacterial counts.
2.5. MIC and MBC Testing. The MICs and MBCs were
determined using an agar-dilution method according toEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Chemical structures of compounds (1) and (2)f r o mI. balsamina L.: (1) 2-methoxy-1,4-naphthoquinone (MeONQ); (2)a n d
stigmasta-7,22-diene-3β-ol (spinasterol).
Wang and Huang [22]. The test compound was dissolved in
dimethyl sulfoxide (DMSO) and 2-fold diluted in Columbia
agarcontaining5%(v/v)deﬁbrinatedsheepblood.Avolume
of 0.1mL of H. pylori suspension (0.5–2.0 × 107 cfumL−1)
was spread onto a Columbia agar plate containing 5%
(v/v) deﬁbrinated sheep blood. After incubation in a
microaerophilic jar system (5% O2 and 10% CO2 in air)
at 37◦C for 72h, the colonies formed on the plate were
enumerated. AMX and MTZ (Sigma-Aldrich, St. Louis, MO,
USA) were used as the positive controls. Experiments were
performed in triplicate. The MIC was deﬁned as the lowest
concentration of the test sample at which no colonies of the
test H. pylori o nt h ep l a t ew e r ef o r m e d .
For MBC testing, the test compound was dissolved in
DMSO and 2-fold diluted in Columbia agar containing
5% (v/v) deﬁbrinated sheep blood or TSB, and was then
individually added to test tubes, with Columbia agar slant
formed at the bottom of the test tube and the TSB layer to
be covered on the slant, both the slant and broth containing
the same concentrations of the test compound. Helicobacter
pylori suspensions were added to the TSB layer to produce
2–8 × 105 cfumL−1 of the initial bacterial counts. The
suspension was then incubated in a microaerophilic jar
system (5% O2 and 10% CO2 in air) at 37◦C for 72h. A
volume of 0.1mL of each suspension was spread onto a
Columbia agar plate containing 5% (v/v) deﬁbrinated sheep
blood, without the test compound. After being incubated
in a microaerophilic jar system (5% O2 and 10% CO2 in
air) at 37◦C for another 72h, the colonies formed were
subsequently enumerated. AMX and MTZ were used as the
positive controls. Experiments were performed in triplicate.
The MBC was deﬁned as the lowest concentration of the test
samplegivingcompleteinhibitionofcolonyformationofthe
test H. pylori at the latter cultivation.
2.6. Time-Kill Assay of MeONQ. Forty milliliters of
Columbia agar containing 5% (v/v) deﬁbrinated sheep
blood and 0–2.5μgmL −1 (control, 1, 2 and 4 times MBC)
MeONQ were added to a 250mL ﬂask to create a plate at
the bottom of the ﬂask. Fifty milliliters of TSB containing
the same concentrations of MeONQ were poured onto
the plate. A volume of 1mL of the H. pylori ATCC 700824
suspension was added to the TSB layer to produce the initial
bacterial concentrations of 2–8 × 105 cfumL−1. The broth
was incubated in a microaerophilic jar system (5% O2 and
10% CO2 in air) at 37◦C for 72h. At various intervals during
the incubation period, the broths were taken and diluted
by 10-fold in 0.1% peptone solution. A volume of 0.1mL
of each suspension was spread onto Columbia agar plate
containing 5% (v/v) deﬁbrinated sheep blood, without
MeONQ. After incubation in a microaerophilic jar system
(5% O2 and 10% CO2 in air) at 37◦C for 72h, the colonies
formed on the plate were enumerated. Experiments were
performed in triplicate.
2.7. Eﬀect of pH of MeONQ. The eﬀects of pH of MeONQ
on the bactericidal activity against H. pylori was determined.
Five milliliters of the Columbia agar containing 5% (v/v)
deﬁbrinated sheep blood at the ﬁnal concentrations of 0–
1.25μgmL −1 (control, MIC, and 1 and 2 times MBC) of
MeONQ was added to test tubes to create slants at the
bottom. Four milliliters of TSB (adjusted to pH 2–8 with 3N
HCl or 3N NaOH) containing the same concentrations of
MeONQ was poured onto the slants. A volume of 0.1mL
of the H. pylori ATCC 700824 suspension was added to
the TSB layer to produce the initial bacterial concentrations
of 2–8 × 105 cfumL−1. The broth was incubated in a
microaerophilic jar system (5% O2 and 10% CO2 in air) at
37◦C for 24h. Each of the broth was sampled and diluted
by 10-fold in 0.1% peptone solution. A volume of 0.1mL
from each of the diluted sample was spread onto Columbia
agar plates containing 5% (v/v) deﬁbrinated sheep blood,
without MeONQ. After incubation in a microaerophilic
jar system (5% O2 and 10% CO2 in air) at 37◦Cf o r
72h, the colonies formed on the Columbia agar plate were
enumerated. Experiments were performed in triplicate.
2.8. Thermal Stability of MeONQ. The thermal stability of
MeONQ on bactericidal activity against H. pylori ATCC
700824 was determined. MeONQ was prepared with DMSO
attheconcentrationof7.5mgmL−1 andheatedat50,70,and
100◦C for 30min; and 121◦C for 15min, then, immediately
cooled in an ice bath. The treated MeONQ was subjected to4 Evidence-Based Complementary and Alternative Medicine
the MIC testing. Unheated MeONQ was used as the control.
Experiments were performed in triplicate.
2.9. MeONQ Levels in I. balsamina. L. MeONQ levels in
the diﬀerent parts (pods, ﬂowers, seeds, roots, stems and
leaves)ofI.balsaminaL.weredeterminedbyaHitachiHPLC
system (Tokyo, Japan) consisting of a Model L-7100 pump
equipped with a multi-solvent delivery systemand an L-7455
photodiode array detector. The column was a Mightysil RP-
18GP, 5μm, 4.6mm in internal diameter (i.d.), and 250mm
in length (Kanto, Tokyo, Japan). The sample preparation was
the same as the aforementioned, and 95% ethanol was used
as the extraction solvent. The mobile phase was composed
of a mixture of 2% acetic acid aqueous-methanol (1/1, v/v).
An isocratic elution mode with 1.0mL min−1 of ﬂow rate
w a sd o n e .T h eU Va b s o r b a n c ew a sd e t e c t e da t2 4 8n m .T h e
operatingtemperaturewasmaintainedatroomtemperature.
Experiments were performed in triplicate.
2.10. Statistical Analysis. Data for time-kill assay, eﬀect of
pH for MeONQ, and MeONQ levels in I. balsamina L. were
subjected to analysis of variance, and a t-test was used to
identify signiﬁcant diﬀerences among the means (P < .05).
3. Results
3.1. Isolation and Structure Elucidation of Anti-H. pylori
Compounds. ThepodextractofI.balsaminaL.wassubjected
to silica gel column chromatography to produce compound
(1).Compound(1)wasidentiﬁedasMeONQbycomparison
ofthespectroscopicdatawiththoseoftheknowncompound
[8, 16]. The n-hexane fraction of roots/stems/leaves extract
of I. balsamina L. was subjected to silica gel column
chromatography to give compound (2). Compound (2)
was identiﬁed as stigmasta-7,22-diene-3β-ol (spinasterol) by
comparison of the spectroscopic data with those of the
known compound [8, 16, 20]. The chemical structures of
MeONQ and spinasterol are shown in Figure 1.
3.1.1. MeONQ (Compound 1). Yellow powder; m.p. 182–
184◦C; UV (MeOH) λmax 243, 248, 278, 338nm; FTIR (KBr)
vmax 1682 (C=O), 1648 (C=O), 1605 (C=C, Ar), 1244 (C–O)
cm−1;f o r1Han d13CNMR,seeTable 1;EI-MS(+70eV)m/z
188 [M]+ (31), 173 [M−CH3]+ (18), 158 [M−OCH2]+ (14),
102 (46), 89 (100).
3.1.2. Spinasterol (Compound 2). White powder; m.p.
164–166◦C; UV (EtOH) λmax 203, 274nm; FTIR (KBr)
vmax 3448 (O–H), 2941 (C–H), 2869 (C–H), 1654
(C=C) cm−1;f o r1Ha n d13CN M R ,s e eTable 1;E I -
MS (+70eV) m/z 412 [M]+ (32), 397 [M−CH3]+ (13),
394 [M − H2O]+ (2), 379 [M−CH3−H2O]+ (2), 369
[M−C3H7]+ (18), 351 (7), 300 [M−C3H12O]+ (16),
271 [M−C10H19−2H]+ (100), 255 [M−C10H19−H2O]+
(50), 253 [M−C10H19−H2O−2H]+ (19), 246 (23), 231
[M−C10H19−C3H6]+ (18), 229 [M−0C10H19−C3H8]+
(22), 213 [M−0C10H19−C3H6−H2O]+ (19), 211
[M−C10H19−C3H8−H2O]+ (3).
Table 1: 1Ha n d13C NMR (600 and 150MHZ, δ ppm, CDCl3)
spectral data for compounds (1) and (2).
C/H (1)( 2)
1H 13CN M R 1H 13CN M R
1 180.1 37.1
2 160.4 31.5
3 6.19 s 109.9 3.60 (1H, m) 71.0
4 184.9 38.0
5 8.13 dd
(1.2, 7.2)
126.7 40.2
6 7.76 td
(1.2, 7.2)
134.4 29.6
7 7.73 td
(1.2, 7.2)
133.4 5.15 (1H, t, J =
12.0 HZ)
117.4
8 8.10 dd
(1.2, 7.2)
126.2 139.5
9 131.0 49.4
10 132.0 34.2
11 3.92 s 56.4 21.5
12 39.4
13 43.3
14 55.1
15 23.0
16 28.5
17 55.8
18 0.55 (3H, s) 12.0
19 0.79 (3H, s) 13.0
20 40.8
21 1.02 (3H, d, J =
6.6 HZ)
21.1
22 5.15 (1H, dd, J
= 9.0, 15.0 HZ)
138.2
23 5.02 (1H, dd, J
= 8.7, 15.3 HZ)
129.4
24 51.2
25 31.9
26 0.80 (3H, d, J =
4.2 HZ)
19.0
27 0.85 (3H, d, J =
5.4 HZ)
21.4
28 25.4
29 0.80 (3H, t, J =
6.0 HZ)
12.3
3.2. MICs and MBCs for MeONQ and Spinasterol. The MICs
and MBCs for MeONQ and spinasterol are listed in Table 2.
Both MICs and MBCs for MeONQ were relatively low, in the
rangesof0.156–0.625and0.313–0.625μgmL −1,r especti v ely .
Compared with the positive controls, the MICs and MBCs
of MeONQ were 25–400% of AMX (0.078–2.5 and 0.156–
2.5μgmL −1 ofMICsandMBCs,resp.);andmuchlowerthan
those of MTZ (160–5120μgm L −1 of both MICs and MBCs).
MeONQ demonstrated very good anti- and bactericidal H.Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Time-kill assay for MeONQ against H. pylori ATCC
700824: control (open circles), 0.313μgmL −1 (ﬁlled triangles),
0.625μgmL −1 (inverted open triangles), 1.25μgmL −1 (inverted
ﬁlled triangles). Data points presented are in mean ± standard
deviation (SD) (n = 3).
pylori activity against CLR, MTZ, and LVX-resistant H.
pylori, which was equivalent to that of AMX.
Both MICs and MBCs for spinasterol against six strains
of CLR, MTZ and LVX-resistant H. pylori were 20–80μg
mL−1 (Table 2). Compared with the positive controls, both
the MICs and MBCs for spinasterol were higher than AMX
and lower than MTZ.
3.3. Time-Kill Assay of MeONQ. As Figure 2 illustrates, three
treatments (0.313, 0.625, and 1.25μgm L −1) initially reduced
survival counts signiﬁcantly by 0.37–0.53 log cfu mL−1
compared with the control. The 0.313 and 0.625μgm L −1
treatments (1 and 2 times MBC, resp.) reduced H. pylori
survival counts from 5.10 ± 0.18–5.18 ± 0.16 log cfu mL−1
to 0 after 24h cultivation; when the treated dose increased
to 1.25μgm L −1 (four times MBC), the survival counts
were reduced to 0 after 8h. The bactericidal action between
the three treated does was signiﬁcantly diﬀerent (P < .05),
indicatingthatthebactericidalH.pyloriATCC700824action
of MeONQ was dose-dependent.
3.4. Eﬀect of pH of MeONQ. In Figure 3,a tp H≤ 3, the
survival H. pylori ATCC 700824 counts were zero for all of
thetreatmentsincluding the controlbecausethose pH values
stopped the bacterial growth. At pH 4–8, when the treated
dose (0.156μgm L −1) was below the MBC (0.313μgm L −1),
MeONQ reduced H. pylori ATCC 700824 survival counts by
1.84–2.91cfu mL−1 after 24h cultivation; while the treated
doses were equal to or higher than the MBC, survival counts
in all the treatments (pH 4–8) were reduced to zero after 24h
cultivation. The bactericidal H. pylori activity of MeONQ
was not inﬂuenced by the environmental pH values (4–8).
3.5. Thermal Stability of MeONQ. After heat treatments
(heating at 50, 70, and 100◦C for 30min; and 121◦Cf o r
pH
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Figure 3: Eﬀe c to fp Ho fM e O N Qo nt h eb a c t e r i c i d a la c t i v i t y
against H. pylori ATCC 700824: control (open circles), 0.156μg
mL−1 (ﬁlled diamonds), 0.313μgm L −1 (ﬁlled triangles), 0.625μg
mL−1 (inverted open triangles). Data points presented are in mean
± SD (n = 3).
15min) of MeONQ, the MICs for the heat-treated MeONQ
against H. pylori ATCC 700824 and KMUH 4917 (0.156
and 0.313μgm L −1, resp.) were the same as the untreated
MeONQ, which indicated that MeONQ’s anti-H. pylori
activity was not altered even after strong heat treatment.
3.6. MeONQ Levels in the Parts of I. balsamina. L. As shown
in Table 3, the I. balsamina L. pods had the greatest amount
of MeONQ (43.92 ± 1.56mg g−1 db) which was 8–150 times
that of the other parts. The MeONQ level in the ﬂowers then
followed at 5.45 ± 0.11mg g−1 db. The levels in the parts of
roots, stems, leaves and seeds were low (0.29 ± 0.00 to 0.56 ±
0.02mg g−1 db) (P < .05).
4. Discussion
In this study, anti-H. pylori compounds, MeONQ and
spinasterol, were isolated from I. balsamina L. Such anti-
and bactericidal H. pylori activity had never been reported
in those compounds. Especially, MeONQ exhibited relatively
low MICs and MBCs against CLR, MTZ and LVX-resistant
H. pylori. This activity was neither inﬂuenced by the
environmental pH value nor strong heat treatment.
Numerous anti-H. pylori compounds including pheno-
lics [23], ﬂavonoids [24], triterpenoids [25], quinones [26]
and others [27] were isolated from natural products. The
MICs for those compounds varied from 1.3 to 200μgmL −1,
however, none of them were lower than 1μgm L −1.C o m -
pared withourcompounds, MICs forMeONQagainstsix H.
pyloristrainsrangedfrom0.156to0.625μgmL −1 whichwere
much lower than those of the aforementioned compounds.
In addition, those values were similar to AMX and much
lower than MTZ (Table 2). MeONQ is the most eﬀective
bactericidal H. pylori natural compound which has thus far
been reported.6 Evidence-Based Complementary and Alternative Medicine
Table 2: MICs and MBCs for MeONQ and spinasterol against H. pylori.
Strain MIC (μgm L −1)M B C ( μgm L −1)
MeONQ Spinasterol AMX MTZ MeONQ Spinasterol AMX MTZ
ATCC 700824 0.156 20 0.078 160 0.313 20 0.156 320
ATCC 43504 0.313 20 0.078 2560 0.625 40 0.156 2560
ATCC 43526 0.625 80 0.156 160 0.625 80 0.156 160
KMUH 4917 0.313 20 0.313 160 0.625 40 0.313 160
KMUH 4952 0.625 80 2.5 5120 0.625 80 2.5 5120
KMUH 4967 0.625 80 0.625 160 0.625 80 0.625 160
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Figure 4: The hypothetical diagram for MeONQ that leads H. pylori death. MeONQ: 2-methoy-1,4-naphthoquinone; MeONQH2:
hydroquinone derivative of MeONQ; MeONQH−: anion form of MeONQH2; MeONQ−•: semiquinone derivative of MeONQ; Re-MeONQ:
regenerated MeONQ; ROS: reactive oxyge species.
We suppose that the mechanisms for the bacterici-
dal H. pylori activity of MeONQ is due to the high
redox potential of its hydroquinone form [28]. MeONQ
is a quinone. Quinones are metabolized by ﬂavoenzymes
(such as NADPH-cytochrome P-450 reductase and xanthine
oxidase) to form hydroquinones. The hydroquinones are
quite unstable, which react with molecular oxygen to form
semiquinones and superoxide anion radicals at physiological
pH. Under aerobic conditions, the semiquinone free radicals
are most likely to react with molecular oxygen to form
superoxide anion radicals and quinones. The regenerated
quinones react with anion form of hydroquinones resulting
in large amounts of reactive oxygen species (ROS). These
ROS can damage a number of cellular macromolecules and
may lead to cell or microorganism death [28–30]. The
hypothetical diagram is presented in Figure 4.
Resistance to antibiotics are the greatest factor in H.
pylori eradication failure, especially to MTZ and CLR.
Resistance rates have increased annually over the last 15
years [4, 31]. For instance, the rates of 7.7% cross-resistance
between MTZ and CLR in Poland and 21.7% between
erythromycin and CLR in Ireland were reported [32, 33].
Thus, killing H. pylori is becoming more and more diﬃcult.
Inourstudy,MeONQnotonlyexhibitedrelativelygoodanti-
and bactericidal H. pylori activity but was also an eﬀective
bactericide against CLR, MTZ and LVX-resistant H. pylori.Evidence-Based Complementary and Alternative Medicine 7
Table 3: MeONQ levels in the diﬀerent parts of I. balsamina L.
Sample MeONQ (mg g−1 dba)
Pod 43.92 ± 1.56a
Flower 5.45 ± 0.11b
Root 0.35 ± 0.01c
Stem 0.56 ± 0.02c
Leaf 0.29 ± 0.00c
Seed 0.37 ± 0.00c
Values presented are in mean ± SD (n = 3). Means followed by diﬀerent
letters are signiﬁcantly diﬀerent (P < .05).
aDried base.
AMX and CLR were not stable in aqueous solutions of
pH lower than 4.0 and 5.0, respectively [34], and therefore
degrade rapidly at normal gastric pH (1.0–2.0). From our
results (Figure 3), both anti- and bactericidal H. pylori
activity of MeONQ were not inﬂuenced by the environ-
mental pH values (4, 8). Moreover, MeONQ exhibited very
good thermal stability, even when heated at 121◦Cf o r
15min. These physicalproperties highlyincreased MeONQ’s
eﬃciency in H. pylori eradication.
In this study, we ﬁrst revealed that MeONQ abound in
the I. balsamina L. pod as high as 43.92 ± 1.56mg g−1
db (Table 3). As previously reported, MeONQ levels in the
leaves, stems and ﬂowers of I. glandulifera Royle were 1.98,
1.33, and 4.86mg g−1 db, respectively [10]; and that of levels
in 40 I. balsamina L. leaf samples were in a range of 0.3–
1.9mg g−1 db [8]. Our MeONQ level in the leaves of I.
balsamina L. was similar to Panichayupakaranant et al. [8],
lower than Lobstein et al. [10], and the level of that in the
ﬂowers was similar to Lobstein et al. [11].
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